A new treatment

Read More

Our Goal

Ischemic stroke is the second leading cause of death and a major cause of disability. Avilex Pharma investigates a novel principle in treatment to meet this major medical need.


Avilex Pharma develops novel inhibitors of PDZ domain proteins to target a range of unmet medical needs. Our lead candidate AVLX-144 is a drug candidate for the treatment of ischemic stroke.

Read More

The Company

Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Ass. Prof. Anders Bach of the Department of Drug Design and Pharmacology.

Read More

Latest News

Avilex Pharma and key partners receive an investment of DKK 20 mill. (total budget DKK 26 mill. / $4.0 mill.) from Innovation Fund Denmark to bring AVLX-144 to the clinic and develop a new PET marker.

Read More
© Copyright 2020 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK